Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia

被引:305
作者
Jain, A
Ma, CA
Liu, SY
Brown, M
Cohen, J
Strober, W
机构
[1] NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA
[3] NIH, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA
关键词
D O I
10.1038/85277
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The gene that encodes nuclear factor kappaB (NF-kappaB) essential modulator (or NEMO, also known as IKK gamma) is required for activation of the transcription factor NF-kappaB. We describe mutations in the putative zinc-finger domain of NEMO that result in an X-linked primary immunodeficiency characterized by hyper-IgM syndrome and hypohydrotic ectodermal dysplasia (XHM-ED). These mutations prevent CD40 ligand (CD40L)-mediated degradation of inhibitor of NF-kappaB alpha (I kappaB-alpha) and account for the following observations: B cells from XHM-ED patients are unable to undergo immunoglobulin class-switch recombination and antigen-presenting cells (APCs) are unable to synthesize the NF-kappaB-regulated cytokines interleukin 12 (IL-12) or tumor necrosis factor alpha (TNF-alpha) when stimulated with CD40L. Nevertheless, innate immunity is preserved in XHM-ED patients because APCs retain the capacity to respond to stimulation by lipopolysaccharide or Staphylococcus aureus Cowan's antigen (SAC). Overall, the phenotype observed in XHM-ED patients shows that the putative zinc-finger domain of NEMO has a regulatory function and demonstrates the definite requirement of CD40-mediated NF-kappaB activation for B cell immunoglobulin class-switching.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 30 条
[1]  
ABBAS A, 1998, CELLULER MOL IMMUNOL
[2]   Toll-like receptors in the induction of the innate immune response [J].
Aderem, A ;
Ulevitch, RJ .
NATURE, 2000, 406 (6797) :782-787
[3]   CD40 LIGAND GENE DEFECTS RESPONSIBLE FOR X-LINKED HYPER-IGM SYNDROME [J].
ALLEN, RC ;
ARMITAGE, RJ ;
CONLEY, ME ;
ROSENBLATT, H ;
JENKINS, NA ;
COPELAND, NG ;
BEDELL, MA ;
EDELHOFF, S ;
DISTECHE, CM ;
SIMONEAUX, DK ;
FANSLOW, WC ;
BELMONT, J ;
SPRIGGS, MK .
SCIENCE, 1993, 259 (5097) :990-993
[4]   CD40 LIGAND AND ITS ROLE IN X-LINKED HYPER-IGM SYNDROME [J].
CALLARD, RE ;
ARMITAGE, RJ ;
FANSLOW, WC ;
SPRIGGS, MK .
IMMUNOLOGY TODAY, 1993, 14 (11) :559-564
[5]   Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain [J].
Deng, L ;
Wang, C ;
Spencer, E ;
Yang, LY ;
Braun, A ;
You, JX ;
Slaughter, C ;
Pickart, C ;
Chen, ZJ .
CELL, 2000, 103 (02) :351-361
[6]   CD40 LIGAND MUTATIONS IN X-LINKED IMMUNODEFICIENCY WITH HYPER-IGM [J].
DISANTO, JP ;
BONNEFOY, JY ;
GAUCHAT, JF ;
FISCHER, A ;
DESAINTBASILE, G .
NATURE, 1993, 361 (6412) :541-543
[7]   NF-κB and rel proteins:: Evolutionarily conserved mediators of immune responses [J].
Ghosh, S ;
May, MJ ;
Kopp, EB .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :225-260
[8]  
Grammer AC, 1998, J IMMUNOL, V161, P1183
[9]   CD40 and CD154 in cell-mediated immunity [J].
Grewal, IS ;
Flavell, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :111-135
[10]  
HAN SH, 1995, J IMMUNOL, V155, P556